Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Observation on the Efficacy of Aflibercept 8mg Intravitreal Injection Solution on Retinal Fluid in nAMD Patients With PED (Fluid-8)

16 de noviembre de 2026 actualizado por: Honghua Yu,MD

Observation on the Efficacy of Aflibercept 8mg Intravitreal Injection Solution on Retinal Fluid in nAMD Patients With PED: a Multicenter, Prospective Study

Primary Objective: To describe the changes in macular fluid within 12 months in patients with neovascular agerelated macular degeneration (nAMD) complicated by pigment epithelial detachment (PED) receiving 8mg aflibercept treatandextend (T&E) therapy.Secondary Objectives:(1) To explore the correlation between changes in macular fluid (e.g., fluctuation index [FI], volume change, etc.) and visual acuity improvement;(2) To evaluate the associations of macular fluid changes (e.g., fluctuation index [FI], volume change, etc.) and different types of fluid components with alterations in retinal and choroidal structures (e.g., disruption of the ellipsoid zone, thickness of each retinal layer, choroidal thickness, microstructural parameters on OCT and OCTA, etc.);(3) To assess the safety of 8mg aflibercept injections in nAMD patients with PED (e.g., incidence rates of retinal pigment epithelium (RPE) tear, elevated intraocular pressure, endophthalmitis and thromboembolic events).

  1. Study Design (1) Type: Prospective, single-arm, open-label, multicenter study. (2) Sample size: The sample size was calculated based on the Fluid Index (FI) with reference to the results of the TOWER study. The TOWER study described the 24-month macular fluid fluctuation after intravitreal anti-VEGF therapy (bevacizumab, ranibizumab and 2 mg aflibercept) for nAMD in the real-world setting. This study hypothesizes that 8 mg aflibercept is non-inferior to the above three agents in controlling fluid fluctuation. Based on the TOWER study, the assumed mean FI at Month 12 is 42.9 with an SD of 9.8; a sample size of 38 yields a two-sided 95% confidence interval with a half-width of 3.22. Assuming a 20% dropout rate, the minimum number of patients required to reach the primary endpoint is 48. (3) Rationale for indication: The study population consists of patients with nAMD, for which aflibercept is a first-line treatment. The intervention is intravitreal injection of 8 mg aflibercept, whose efficacy and safety have been demonstrated in previous Phase III clinical trials. The T&E regimen is a globally recognized optimized treatment strategy that reduces the treatment burden on patients and healthcare facilities while maintaining sustained disease control.
  2. Study Procedures This study includes a 3-week screening period to assess subject eligibility, followed by a 48-week treatment period. Subjects who provide consent, meet all inclusion criteria and do not meet any exclusion criteria will receive intravitreal injection of 8 mg aflibercept in the study eye. Referencing the ALTAIR study, this study adopts the T&E (treat-and-extend) regimen: one intravitreal injection is administered at Week 0, Week 4 and Week 8 during the loading phase, and the maintenance phase starts at Week 20. During the maintenance phase, all decisions to extend, maintain or shorten the dosing interval are made according to the T&E criteria. The treatment interval should be shortened if any of the following occurs: new fluid (across all tomographic scans), no improvement or worsening of pre-existing fluid, a loss of ≥5 letters in visual acuity compared with the last visit, an increase of ≥100 μm in CRT in the central 1 mm subfield relative to the previous minimum value, or new neovascularization / new submacular hemorrhage. If the criteria for interval shortening are not met, the current interval will be maintained if fluid persists but shows a continuous decreasing trend; the injection interval may be extended as appropriate if there is no active fluid on OCT. In principle, the injection interval is adjusted within the range of 8-24 weeks, with a default adjustment step of 4 weeks each time.

Descripción general del estudio

Estado

Aún no reclutando

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

48

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

50 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • 1: (1) Age ≥ 50 years old;

    2: (2) Patients with newlydiagnosed or preexisting nAMD and OCTconfirmed PED;

    3: (3) Patients who are planned to initiate intravitreal injection of aflibercept 8 mg;

    4: (4) Patients voluntarily participate in this study, sign a written informed consent form and are willing to cooperate with followup visits;

    5: (5) Patients are assessed by the investigator to have good compliance;

    6: (6) If both eyes meet the enrollment criteria, the study eye shall be selected according to the following rules: ① When the bestcorrected visual acuity (BCVA) of the two eyes is different, the eye with poorer visual acuity shall be selected; ② When the BCVA of the two eyes is the same, the right eye shall be selected by default.

Exclusion Criteria:

  • 1: (1) Insufficient quality of OCT images, which prevents reliable assessment of Central Retinal Thickness (CST) or Ellipsoid Zone (EZ);

    2: (2) Complete absence of the central EZ at baseline, making it impossible to evaluate its changes during followup;

    3: (3) Coexistence of other macular diseases that may interfere with the evaluation of macular structure (e.g., Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), etc.);

    4: (4) Any condition that may affect patient compliance or scheduled followup (e.g., severe mental disorders, cognitive impairment, substance abuse or addiction, etc.);

    5: (5) Participation in any other clinical research project, or having taken part in any drug clinical trial within 6 months prior to screening examinations;

    6: (6) Presence of any contraindications listed in the prescribing information for Aflibercept 8 mg;

    7: (7) Extraocular/periorbital or intraocular infection or inflammation in either eye at the time of the first study drug injection;

    8: (8) The fellow eye is receiving other intravitreal treatments other than Aflibercept;

    9: (9) The study eye has received intravitreal antiVEGF injections within the past 3 months, intravitreal glucocorticoid therapy within the past 3 months, or a dexamethasone intravitreal implant within the past 6 months;

    10: (10) The patient has a history of immunodeficiency diseases (e.g., HIV, etc.), cancer or malignant tumors, autoimmune diseases, severe cardiovascular or cerebrovascular diseases, or other illnesses that may significantly reduce life expectancy;

    11: (11) Pregnant or lactating women, or women of childbearing potential who are unwilling or unable to use effective contraceptive measures;

    12: (12) Known hypersensitivity to any ingredients contained in the study drug;

    13: (13) Patients deemed unsuitable for participation in this study by the investigator.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Otro: Aflibercept 8mg

Intravitreal Injection of Aflibercept 8 mg

Intravitreal Injection of Aflibercept 8 mg

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Fluctuation Index
Periodo de tiempo: Day 1, Month 1, Month 2, Week 20, and through Month 12 (T&E phase)

Parameter source: OCTcentral 1mm CST, including foveal retinal thickness and volume.Calculation formula: FI = Sum of absolute changes in CST between all adjacent visits from baseline to M12 ÷ Number of adjacent intervals.

Day 1, Month 1, Month 2, Week 20, and through Month 12 (T&E phase)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
BCVA
Periodo de tiempo: Day 1, Month 1, Month 2, Week 20, and through Month 12 (T&E phase)

After wearing corrective lenses, outcomes from the ETDRS 4-meter standard protocol or clinical results shall be uniformly converted to ETDRS letter scores; the same method, lighting and distance shall be maintained for the same subject throughout follow-up assessments.

Day 1, Month 1, Month 2, Week 20, and through Month 12 (T&E phase)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

15 de noviembre de 2026

Finalización primaria (Estimado)

30 de septiembre de 2028

Finalización del estudio (Estimado)

30 de septiembre de 2028

Fechas de registro del estudio

Enviado por primera vez

4 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • MR-44-26-077408

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir